Joseph S. McCracken
Lead Independent DirectorDr. Joseph S. McCracken, D.V.M. MS & Ph.D. also known as Joe, was Advisor of Acepodia, Inc until 2025. He served as a Head of Business Development of Acepodia, Inc. since 2022. He served as a Head of Business Development at AltruBio, Inc until 2022. He had been a Senior Vice President of Business Development at Acepodia Inc. until 2022. He serves as Outside Independent Director of Modalis Therapeutics Corporation since August 2018. He is an Advisor at Charlbury Animal Health GmbH. He served as Independent Director of Kindred Biosciences, Inc. since April 2018. He served as Independent Director of Lumos Pharma, Inc. since March 23, 2020. He serves as Vice President of Business Development at Alkahest, Inc. Dr. McCracken is a Consultant to biotechnology companies. From July 2011 to September 2013, he served as Vice President and Global Head of Business Development & Licensing for Roche Pharma, a research-focused healthcare company, where he was responsible for Roche Pharma’s global in-licensing and out-licensing activities. From October 2009 to July 2011 Dr. McCracken was General Manager, Roche Pharma Japan & Asia Regional Head, Roche Partnering. Prior to joining Roche Pharma, Dr. McCracken served as Vice President of Business Development at Genentech Inc. He served as Director of Business Development at Genentech Ltd. Dr. McCracken served as Head of Strategic Pipeline Development of Genentech Inc. since April 2004. He has experience in technical, business development and market development roles with biotechnology and pharmaceutical companies. Dr. McCracken served as Vice President of Technology Licensing and Alliances at Aventis Pharmaceuticals from January 2000 to July 2000. He served as Director of Neuropore Therapies, Incorporated from July 2011 to September 2013. He served as Vice President of Worldwide Business and Technology Development of Rhone-Poulenc Rorer Pharmaceuticals from November 1998 to December 1999 and served as its Vice President of Technology Licensing from November 1997 to November 1998. Dr. McCracken founded TPM Associates in April 1995. From October 1993 to April 1995, he served as Vice President of Business Development of Terrapin Technologies. Dr. McCracken advises biopharmaceutical companies on the design and implementation of corporate strategy and business development initiatives. He served as Director at Nexvet Australia Pty Ltd from September 2014 to July 31, 2017. Dr. McCracken serves as Director at REGiMMUNE Corporation since December 25, 2015. He is Observer of GenKyoTex SA since February 28, 2017 and also served as its Director since May 2014. He has been Independent Director at Savara Inc. since October 2013 and also has been its Lead Independent Director since December 2019. Dr. McCracken serves as a Board Member at Biotechnology Companies. He serves as a Director of Alkahest, Inc. Dr. McCracken served as a Representative Director of Genentech Ltd. He served as an Independent Non-Executive Director of Nexvet Biopharma Public Limited Company since September 2014 until July 31, 2017. Dr. McCracken holds a BSc in Microbiology, an MSc in Pharmacology and a Doctorate of Veterinary Medicine from The Ohio State University.
Positions
- Company NameSavara Inc.Stock CodeSVRAPositionLead Independent Director
